

Protocol

Mouse TrueBlot® Set (IP Agarose Beads)

Rockland's Mouse TrueBlot® Set (88-7788-31) combines the specificity and unique detection properties of TrueBlot® secondary antibodies with the exceptional purification of TrueBlot® anti-mouse Ig IP beads. The HRPconjugated TrueBlot® anti-mouse IgG secondary antibody supplied in the set recognizes the native, non-reduced form of mouse IgG over the reduced form of mouse IgG, which eliminates interference from the denatured/ reduced heavy and light chain bands of the IP antibody present in the immunoprecipitated sample. Using the Mouse TrueBlot® Set easily accommodates the detection of proteins with overlapping molecular weights to the heavy and light chain to provide accurate, publication-quality IP-Western Blots. This protocol is intended for use in the Western blot of immunoprecipitated samples (IP-Western Blot), in which the same antibody (or species) is used for both the IP and Western Blot (WB) steps.

Components

Product	Size	Item No.
1000X Mouse TrueBlot Anti-Mouse IgG Secondary Antibody (HRP)	50 µL	18-8817-31
TrueBlot Anti-Mouse Ig IP Agarose Beads	2.5 mL	00-8811-25

Note: Do not vortex the agarose IP beads as it may cause damage. Agarose IP beads are in suspension and settle upon storage. Mix vial well by gentle inversion to ensure delivery of the proper bead volume prior to use.

Reagents Required

Collection of Cell Lysate

Product	Preparation	Item No.
UltraPure Sterile Water		MB-009-1000
1X PBS, pH 7.2	Dilute 10X PBS, pH 7.2 to 1X with UltraPure Sterile Water; keep on ice.	MB-008
Cell Lysis Buffer ¹	Add appropriate volume of protease/phosphatase inhibitors to recommended final concentration from manufacturer prior to use.	
Cell Scraper		
Protease and Phosphatase Inhibitors ²		

Immunoprecipitation

Product	Preparation	Item No.
---------	-------------	----------

Wide-bore Pipet Tips	Or cut pipet tip for pipetting agarose bead suspension
IP Buffer ³	Add appropriate volume of protease/phosphatase inhibitors to recommended final concentration from manufacturer prior to use.

IP Antibody

SDS-PAGE/Western Blot

Product	Preparation	Item No.
2X SDS-PAGE Sample Buffer without DTT	Or β -ME or Laemmli equivalent	MB-018
1 M DTT or 14.3 M β -Mercaptoethanol		
2X SDS-PAGE Sample Buffer with reducing agent ⁴	Add DTT to a final concentration of 50 mM or add β -Mercaptoethanol to a final concentration of 2% (v/v)	
Opal Prestained Protein Standard	10–245 kDa or 10–180 kDa	MB-201-0500 / MB-209-0500
10X SDS-PAGE Running Buffer or running buffer equivalent		MB-017
Transfer Buffer ⁵		
Ponceau S Solution		MB-072-500
5% BLOTTO in 1X TBST		B501-0500
Primary Antibody (for WB)		
1X TBS-T (0.1% Tween)	Dilute 10X TBS, pH 7.5 with UltraPure Sterile Water or equivalent to 1X, TWEEN® 20 ⁶	MB-012 / MB-009-1000
Chemiluminescent Femtomax™ Super Sensitive HRP Substrate		FEMTOMAX-020
0.20 μ m or 0.5 μ m PVDF or nitrocellulose membrane		
Forceps (blunt end)		
		WIB-2875-010 /
Membrane Incubation Trays		WIB-4625-005

¹RIPA and NP-40 (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1% NP-40) are commonly used lysis buffers. For optimal results, choose a lysis buffer that is most compatible with your protein of interest and downstream IP application. If running protein assays prior to SDS-PAGE, be sure the components of your lysis buffer are compatible with your choice of assay.

²The type of protease and phosphatase inhibitors used, as well as the final working concentration, varies and should be optimized by the end user. However, a suggestion of final concentrations for a general protease inhibitor cocktail is 1.0 mM PMSF, 10 μ M leupeptin, 0.1 μ M aprotinin, and 1.0 μ M pepstatin. The recommended final

concentration for phosphatase inhibitors is 1.0 mM Na₃VO₄ and 1 mM NaF. A variety of cocktails are also available commercially.

³Use of standard IP buffers for binding and wash steps, such as 1X PBS or 1X TBS with or without low concentrations of gentle detergent, as well as other IP buffers should be optimized by the end user for their specific immune complex. If using cell lysis buffer in these steps, take into consideration the detergent type and concentration, as these factors may disrupt native structure or protein-protein interactions.

⁴Prepare reducing 2X SDS sample buffer fresh and use within the hour. Discard remainder. Concentration of reducing agents can be increased, if needed.

⁵Choose transfer buffer based on protein of interest, gel type, membrane, and transfer type.

⁶The final TWEEN 20 concentration used in the 1X TBS-T buffer may be adjusted if necessary (0.01–0.1%) when optimized by the end user.

Equipment Required

1. Pre-cooled Centrifuge (4°C)
2. Rocking Platform
3. Rotator
4. Heat Block
5. SDS-PAGE and Western Blot Equipment
6. Imaging System (compatible with chemiluminescence) or dark room and equipment for x-ray film

Procedure for Cell Lysate Preparation

1. Aspirate or pipet off cell culture media. Wash with ice-cold 1X PBS, then remove 1X PBS.
2. Harvest approximately 1×10^7 cells by using a cell scraper and transfer to a conical tube. If working with adherent cells, you can skip this step and lyse directly on the plate (see step 5).
Note: The total number of cells per mL and the cell equivalent loaded per lane of gel should be optimized specifically for each protein and antibody. Alternatively, protein concentration can be determined using a protein assay.
3. Wash cells with ~10 mL of cold 1X PBS and centrifuge at 400 x g for 10 minutes at 4°C. **Note:** If using adherent cells, wash cells on the plate while keeping the plate on ice.
4. Discard the supernatant and repeat step 3.
5. After the second wash, remove the supernatant and resuspend the cell pellet in 1 mL of cold Lysis buffer containing protease inhibitors. The final concentration of cells should be about 1×10^7 cells/mL.
Note: If using adherent cells, the cold lysis buffer can be added directly to the plate and put on a rocker at 4°C. Harvest by either scraping or collecting just the supernatant. If collecting just the supernatant, proceed to step 8.
6. Gently vortex and transfer to a 1.5 mL microcentrifuge tube.
7. Place on ice for 30 minutes with occasional mixing.
8. Centrifuge at 10,000 x g for 15 minutes at 4°C.

9. Carefully collect the supernatant without disturbing the pellet and transfer to a new, clean 1.5 mL microcentrifuge tube and discard the pellet.
10. The protein concentration can be determined by a protein assay. Samples can be diluted to 1 mg/mL if desired.
11. The cell lysate can be frozen at this point for long-term storage at -80°C.

Procedure for Cell Lysate Preclearing

1. Resuspend the immobilized anti-species-specific IgG bead slurry. Remove 50 µL and wash in lysis buffer or IP buffer, if different. Resuspend in 50 µL of cell lysis buffer or IP buffer. Bead slurry by repeatedly inverting the vial several times. Do not vortex.
2. Add 500 µL of cell lysate (~5 x 10⁶ cells or ~500 µg protein) to the pre-equilibrated bead slurry and incubate on a rocking platform or orbital shaker for 30–60 minutes at 4°C.
3. Centrifuge at 2,500 x g for 2–3 minutes at 4°C and transfer the supernatant to a new 1.5 mL tube. If any of the bead slurry has been transferred, centrifuge again and carefully transfer the supernatant to another fresh 1.5 mL tube.

Procedure for Immunoprecipitation

1. Add 1–10 µg of immunoprecipitation antibody to the tube containing the cold, precleared cell lysate.
Note: This concentration of antibody is suggested as a starting point. Each investigator may desire to titrate the concentration of antibody and volume of cell lysate in preliminary experiments to determine the optimal conditions, e.g., 1–10 µg/1 x 10⁷ cells/1 mL lysate.
2. Typically, 2 µg is a sufficient amount of antibody to maximally immunoprecipitate most antigens in 1 mL of extract from 1 x 10⁷ cells. Using as little IP antibody as possible minimizes potential contamination of SDS-reduced sample with non-reduced immunoprecipitating antibody light chain. It is not recommended to use more than 10 µg (per mL) or a final of 5 µg per lane.
3. Incubate at 4°C for 1 hour on a rocking platform or a rotator.
4. Add at least 50 µL of pre-equilibrated bead slurry to capture the immune complexes.
5. Incubate for 1 hour or overnight at 4°C on a rocking platform or a rotator.
Note: Steps 1 and 3 can be combined for a single incubation. Centrifuge the tube at 2,500 x g for 30 seconds at 4°C.
6. Carefully remove the entire supernatant and wash the beads 3–5 times with 500 µL of cold lysis buffer or IP buffer, centrifuging to pellet beads between each wash. To minimize background, be sure to completely remove the supernatant after each wash.
7. After the last wash, carefully aspirate the supernatant and add 50 µL of SDS reducing sample loading buffer or equivalent to the bead pellet.
Note: 1X or 2X SDS reducing sample buffer can be added to the beads. In-house experiments use 2X. Please take into consideration the composition of the loading buffer. It is important that the sample is completely reduced.
8. Gently vortex and heat samples at 90–100°C for 10 minutes.
9. Centrifuge at 10,000 x g for 5 minutes, carefully collect the supernatant, and load onto the gel.
10. Alternatively, the supernatant samples can be collected, transferred to a clean 1.5 mL microcentrifuge tube and frozen at -80°C, if the gel is to be run at a later time.

11. Follow manufacturer's instructions for SDS-PAGE.

Procedure for Western Blot

1. Following SDS-PAGE, transfer proteins from the gel onto either a PVDF or nitrocellulose membrane. **Note:** For best protein transfer results, follow the instructions provided by the transfer system manufacturer.
Optional: To determine whether the proteins have been transferred to the membrane, stain with a 0.1% Ponceau S solution. Protein bands can be visualized after staining for 5 minutes. To remove the Ponceau S stain, rinse with distilled water or 1X TBS-T until most of the dye is removed before moving on to blocking step. Residual dye will not affect subsequent steps.
2. Block the membrane with 5% BLOTTO solution (w/v) and incubate for 2 hours at room temperature or overnight at 4°C on a rocking platform.
Note: It is recommended to use Milk or BLOTTO as the blocking reagent for HRP-conjugated TrueBlot® secondary antibodies, as BSA may not block the reduced chain as effectively.
3. Prepare the primary immunoblotting antibody in blocking buffer as recommended by the supplier. **Note:** If the recommended concentration is not known, use a standard concentration of 1–2 µg/mL. If using hybridoma tissue culture supernatant or serum for immunoblotting, preliminary experiments should be performed to evaluate whether dilution of the supernatant or serum is needed for best results.
4. Incubate the blot with primary antibody for at least 2 hours at room temperature or overnight at 4°C on a rocking platform.
Note: Specific times should be determined empirically for optimal results.
5. After the incubation of the membrane with the primary antibody, wash the blot at least 3–5 times in 1X TBS-T, each wash for a minimum of 5–10 minutes each. Total should be more than 1 hour.
6. Prepare the TrueBlot® secondary antibody at a 1:1000 dilution in the blocking buffer.
Note: This dilution is intended as an initial recommendation. Specific conditions for each protein and antibody combination should be specifically optimized by the end user. To optimize the detection of mouse IgG1, we recommend performing a dot blot or titration to determine the ideal dilution factor (starting at 1:1000).
7. Incubate the blot with TrueBlot® secondary antibody for 1 hour at room temperature on a rocking platform.
Note: Specific times should be determined empirically for optimal results.
8. Wash the blot at least 3–5 times in 1X TBS-T, each wash for at least 5 minutes each. Total should be more than 1 hour.
9. Develop the blot using a chemiluminescent HRP substrate following the manufacturer's instructions.
10. Image the blot with an imaging system compatible with chemiluminescent detection or by exposing the blot to x-ray film.

Notes

Recommended positive control: Species-dependent IgG TrueBlot® will detect SDS-denatured, non-reduced species-specific IgG. A 20–30 ng sample of non-reduced, immunoprecipitating antibody can be included in the immunoblot as a positive control to ensure positive performance of TrueBlot®.

Recommended negative control: Samples containing 0.5–2.0 ug of reduced species-specific IgG (prepared and run immediately as described in Sample Preparation) can be included as a negative control to ensure that individual TrueBlots® do not detect heavy and light chains of the immunoprecipitating antibodies.

Recommended additional controls:

- Omit the cell extract during the IP
- Omit the IP antibody during the IP
- Omit the immunoblotting antibody

Troubleshooting Guide

Issue	Cause	Solution
No Signal	Weak primary antibody	Use only primary antibodies optimized for immunoblotting
	Primary antibody is not a species-specific IgG	Use only species-specific IgG as primary antibody
	Target is not expressed in the sample or present at low levels	Use a positive control sample known to contain the target protein and optimize the amount of protein loaded
High Background	Non-optimized primary antibody	Use only primary antibodies optimized for immunoblotting.
	Insufficient washing	Increase volume, number, and duration of washes. Increase salt content of the wash buffer
	Membrane was allowed to dry out and was not re-wet	Ensure membrane does not dry during immunoblotting procedure. Immobilon-P and other PVDF membranes must be saturated in methanol and equilibrated in buffer.
	Insufficient blocking	5% (w/v) non-fat dry milk is the best blocking agent. BSA is specifically not recommended.
Ig and the specific band of interest are both seen	Improper sample preparation	Follow sample preparation procedure
	Sample not completely denatured/reduced	Increase amount of reducing/denaturing agent
Other bands besides the specific band of interest are seen	Poor primary antibody (low signal/high noise)	Use primary antibodies optimized for immunoblotting (high signal/low noise)
		Possible different isoforms/modification of the protein of interest

Rockland products are for research use only and are not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Immunochemicals, Inc., P.O. BOX 5199, Limerick, Pennsylvania 19468, USA.

© 2025 Rockland Immunochemicals, Inc. All rights reserved.